[Ambulatory management of community-acquired pneumonia in the adult. II: Therapeutic strategy and follow-up].
In adult outpatients with community-acquired pneumonia, the choice for antibiotherapy is empirical. This choice includes the age and the severity assessment of the patient, and the epidemiology of respiratory pathogens. New fluoroquinolones are not recommended as first line agents. Patients with community-acquired pneumonia had an increased morbidity and mortality. Prevention includes influenza and pneumococcal vaccination, and smoking cessation.
Lamy
O
O
Service de Médecine A, Département de médecine, CHUV, Lausanne. olivier.lamy@chuv.hospvd.ch
D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000401:mortality / Q000517:prevention & control; D005260:Female; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D022242:Pneumococcal Vaccines / Q000008:administration & dosage; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000401:mortality / Q000517:prevention & control; D016540:Smoking Cessation; D015996:Survival Rate
D000900:Anti-Bacterial Agents; D007252:Influenza Vaccines; D022242:Pneumococcal Vaccines